Enbrel Liquid Immunogenicity Protocol

NCT00249041 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 447

Last updated 2010-07-30

No results posted yet for this study

Summary

The purpose of this study is to assess the antibody formation to Enbrel liquid in subjects with Rheumatoid Arthritis

Conditions

Interventions

DRUG

50 mg Etanercept

50 mg Etanercept liquid injected SC once weekly using prefilled syringes

DRUG

Enbrel liquid

50 mg Etanercept liquid injected SC once weekly using prefilled syringes

Sponsors & Collaborators

  • Immunex Corporation

    collaborator INDUSTRY
  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-12-31
Completion
2007-03-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00249041 on ClinicalTrials.gov